A. Rosenquist

发表

Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.

B. Samuelsson, M. Cummings, Magnus Nilsson, 2014, Journal of medicinal chemistry.

Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.

Susanne Nyström, Maxwell D Cummings, Oliver Lenz, 2010, Angewandte Chemie.

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

L. Vrang, B. Samuelsson, Herman A de Kock, 2009, Antimicrobial Agents and Chemotherapy.

Synthesis and Biological activity of kappa opioid receptor agonists. Part 2: preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods.

Magnus J. Johansson, B. Andersson, V. Chhajlani, 2003, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.

Elizabeth Hamelink, L. Vrang, B. Samuelsson, 2004, Journal of medicinal chemistry.

Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.

Elizabeth Hamelink, L. Vrang, B. Samuelsson, 2008, Bioorganic & medicinal chemistry letters.

HIV-1 Protease Inhibitors with a Tertiary Alcohol Containing Transition-State Mimic and Various P2 and P1' Substituents

L. Vrang, B. Samuelsson, T. Unge, 2011 .

2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.

B. Samuelsson, M. Cummings, Christophe Buyck, 2010, Journal of Medicinal Chemistry.

Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.

L. Vrang, J. Unge, M. D. De Rosa, 2014, Journal of medicinal chemistry.

Synthesis, X-ray Analysis, and Biological Evaluation of a New Class of Stereopure Lactam-Based HIV-1 Protease Inhibitors

L. Vrang, B. Samuelsson, J. Unge, 2012, Journal of medicinal chemistry.

Synthesis of potent BACE-1 inhibitors incorporating a hydroxyethylene isostere as central core.

N. Borkakoti, B. Samuelsson, A. Hallberg, 2010, European journal of medicinal chemistry.

P2'-truncated BACE-1 inhibitors with a novel hydroxethylene-like core.

B. Samuelsson, A. Hallberg, H. Adolfsson, 2010, European journal of medicinal chemistry.

Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.

B. Samuelsson, A. Hallberg, J. Unge, 2013, Journal of medicinal chemistry.

Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses

T. Helleday, C. Salata, R. Jafari, 2020, Viruses.

Nucleotide prodrugs of 2'-deoxy-2'-spirooxetane ribonucleosides as novel inhibitors of the HCV NS5B polymerase.

B. Samuelsson, Lili Hu, L. Leclercq, 2014, Journal of medicinal chemistry.

Antiviral Activity and Mode of Action of TMC647078, a Novel Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase

B. Samuelsson, S. Eriksson, L. Leclercq, 2011, Antimicrobial Agents and Chemotherapy.

Discovery of β-d-2'-deoxy-2'-dichlorouridine nucleotide prodrugs as potent inhibitors of hepatitis C virus replication.

P. Targett-Adams, A. Eneroth, Å. Rosenquist, 2017, Bioorganic & medicinal chemistry letters.

Discovery and Development of the HCV Protease Inhibitor TMC435

R. Verloes, P. Raboisson, K. Simmen, 2011 .

Running title: TMC435350, in vitro activity and pre-clinical profile

L. Vrang, B. Samuelsson, P. Wigerinck, 2009 .

Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic.

B. Samuelsson, M. Larhed, Fredrik Wångsell, 2009, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent and selective BACE-1 inhibitors.

N. Borkakoti, L. Vrang, B. Samuelsson, 2010, Journal of medicinal chemistry.

Optimization of a somatostatin mimetic via constrained amino acid and backbone incorporation.

A. Souers, M. Ladlow, J. Ellman, 2000, Bioorganic & medicinal chemistry letters.

Antiviral activity and mode of action of TMC 647078 , a novel 1 nucleoside inhibitor of the HCV NS 5 B polymerase 2 Running title : Characterization of HCV nucleoside inhibitor TMC 647078 3 4

B. Samuelsson, S. Eriksson, L. Leclercq, 2011 .

Solid-phase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II.

Elizabeth Hamelink, L. Vrang, B. Samuelsson, 2003, Bioorganic & medicinal chemistry.

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.

J. Wegner, B. Samuelsson, L. Baert, 2013, Bioorganic & medicinal chemistry letters.

Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.

Anders Hallberg, Guido Zuccarello, L. Vrang, 2004, European journal of biochemistry.

New inhibitors of the malaria aspartyl proteases plasmepsin I and II.

Elizabeth Hamelink, L. Vrang, B. Samuelsson, 2003, Bioorganic & medicinal chemistry.

Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.

L. Vrang, B. Samuelsson, Lili Hu, 2008, Bioorganic & medicinal chemistry letters.

Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.

Elizabeth Hamelink, L. Vrang, B. Samuelsson, 2006, Bioorganic & medicinal chemistry.

Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the beta-turn.

R. Cone, A. Souers, J. Ellman, 1999, Journal of medicinal chemistry.

Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II.

Elizabeth Hamelink, L. Vrang, B. Samuelsson, 2005, Journal of medicinal chemistry.